MedTrace Logo

MMR Vaccination Among HIV-infected Adults

NCT02724852 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 632

Last updated 2016-04-01

No results posted yet for this study

Summary

This is a prevalence study of protective antibodies to measles, mumps, and rubella (MMR) in HIV-infected adults and HIV-uninfected controls. MMR vaccination were provided to both groups who had no protective antibodies to at least one of the three viruses.

Conditions

Interventions

BIOLOGICAL

0.5 ml of MMR vaccine

Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region

Sponsors & Collaborators

  • Chiang Mai University

    lead OTHER

Principal Investigators

  • Romanee Chaiwarith, MD · Chiang Mai University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-09-30
Completion
2014-03-31

Countries

  • Thailand

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724852 on ClinicalTrials.gov